Biosimilars Policy Roundup: July 2024
July brought a lot of discussion regarding biosimilar policies, in both the US and abroad, as well as 3 highly anticipated FDA approvals. FDA Approvals Two approvals came through during the first day of the month: Samsung Bioepis’ Pyzchiva (ustekinumab- …